258 results about "Immunohistochemistry" patented technology

The invention relates to the technical field of biological medicines, and particularly discloses an anti-human CD3 rabbit recombinant monoclonal antibody as well as a preparation method and application thereof. The antibody obtains anti-CD3 immune response by immunizing a rabbit, is obtained by combining single B cell sorting, gene cloning and a mammalian cell expression system, and has high affinity and good specificity. The antibody can effectively recognize CD3 positive T cells in human peripheral blood and can be applied to the fields of flow cytometry, immunohistochemistry, T cell function research and the like. Experimental results show that the antibody has the advantages of high titer, strong fluorescence signal, low background and the like, and is superior to the traditional murine anti-CD3 antibody. Amino acid sequences of light chain and heavy chain variable regions of the antibody are further obtained, and controllability and repeatability of antibody expression are achieved. The antibody has important scientific research value and industrial application prospect, and is suitable for various scenes such as T cell marker detection, immune state evaluation, immunotherapy auxiliary research and the like.

The invention discloses a monoclonal antibody BY017 combined with African swine fever virus P30 protein and application of the monoclonal antibody BY017. The invention provides an IgG antibody which is composed of a light chain and a heavy chain. CDR1, CDR2 and CDR3 in the heavy chain variable region are sequentially shown as the 47 to 54 , the 72 to 79 and the 118 to 126 in SEQ ID NO: 1; cDR1, CDR2 and CDR3 in a light chain variable region are sequentially as shown in the 49 to 60 , the 78 to 80 and the 117 to 124 in SEQ ID NO: 3. The invention also protects the application of any one of the IgG antibodies in preparation of products. The product has the functions that the product is used for being combined with an African swine fever virus P30 protein fragment; the antibody is used for binding African swine fever virus P30 protein; the antibody is used for binding African swine fever virus. The IgG antibody provided by the invention can be used for multiple purposes of western blot, immunohistochemistry, flow cytometry, ELISA (Enzyme-Linked Immunosorbent Assay) and the like, and can be used as an important tool for ASFV detection and structural analysis of P30 protein of ASFV detection.

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-human carbohydrate antigen CA125 monoclonal antibody and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.8-10. The monoclonal antibody provided by the invention can specifically recognize and bind to a natural carbohydrate antigen CA125 expressed by human cells or tissues, has good affinity and relatively high sensitivity of binding of the antibody and the antigen, has strong anti-interference ability to complex non-target protein components in the cells / tissues, is beneficial to significantly improving the accuracy and reliability of immunodetection of human CA125 protein, and has good application prospects. The method is suitable for high-specificity, high-sensitivity and high-reliability detection of the human CA125 protein, and has good applicability in a plurality of detection systems such as immunoblotting, immunoprecipitation, immunohistochemistry and the like.

The invention discloses a pharmaceutical composition for reversing pancreatic cancer gemcitabine drug resistance and application of the pharmaceutical composition, and belongs to the technical field of biological medicine. The composition comprises a generic FGFR inhibitor delatinib and gemcitabine, the concentration of the delatinib is 25 to 50 mg / kg, and the concentration of the gemcitabine is 20 to 30 mg / kg. By inhibiting an FGFR2 / FGFR3 signal channel and reducing the expression of FGFR protein in drug-resistant cells, the chemosensitivity of gemcitabine is synergistically enhanced, the apoptosis induction rate is increased by more than two times, and the synergic index (CI) is less than 1. In-vitro and nude mouse transplantation tumor experiments prove that the composition can significantly inhibit the proliferation of gemcitabine drug-resistant pancreatic cancer cells. The Gemcitabine drug-resistant pancreatic cancer drug can be used for preparing a drug for treating Gemcitabine drug-resistant pancreatic cancer with high FGFR3 expression, patients are screened through immunohistochemistry or gene sequencing, intravenous injection or oral administration is adopted, dosage forms comprise freeze-dried powder injection, capsules or tablets, and a new strategy is provided for pancreatic cancer drug-resistant treatment.

A specific antibody and an antigen binding fragment thereof against a CD228 protein, used for testing and treating multiple tumors, such as melanoma, mesothelioma, and colorectal cancer. An antibody binding fragment facilitates the diagnosis and treatment of cancer by specifically binding to CD228. The present invention further comprises antibody-drug conjugates (ADCs) in which drugs bind to antibodies by means of linkers, aiming to improve the treatment effect and reduce the impact on normal cells. Additionally, the present invention provides a nucleic acid encoding an antibody or an antigen binding fragment thereof, so as to produce a recombinant antibody or fragment. In addition, the present invention further provides a kit, used for laboratory research, clinical diagnosis and treatment effect monitoring, facilitating determination of whether tissues or cells express CD228, providing a new strategy for personalized and accurate treatment of cancer.

The invention discloses application of a cell surface adhesion molecule CD22 as a target spot in preparation of drugs for treating spinal cord injury related diseases. The change of gene expression in the glial scar formation process is represented by space transcriptome sequencing, and the specific expression of CD22 in the glial scar region is up-regulated. According to single cell sequencing, in-situ hybridization and immunohistochemistry, specific high expression CD22 of part of microglial cells in a glial scar area is found. CD22 is knocked out through a genetic means, and it is found that formation of glial scars after spinal cord injury is remarkably reduced through inhibition of CD22. Behavioral detection finds that the error rate of irregular horizontal ladders is remarkably reduced by inhibiting CD22, and fine movement recovery of hind limbs of mice after spinal cord injury is promoted. The siRNA specifically targeting CD22 is injected into the sheath, so that the expression of microglial cells CD22 is inhibited, the error rate of irregular horizontal ladders of hind limbs can be reduced, and the recovery of the fine movement function of the hind limbs of the mouse after spinal cord injury is promoted. The invention provides a new possibility for development of drugs for spinal cord injury and treatment of spinal cord injury.

The invention relates to the technical field of antibodies, and provides an anti-CD45 antibody and application thereof, the antibody comprises at least one of the following CDRs: a heavy chain variable region CDR: an amino acid sequence of SEQ ID NO: 1-3 or a conservatively modified form thereof; and a light chain variable region CDR: SEQ ID NO: 4-6 or an amino acid sequence in a conservative modification form thereof. The antibody or the antigen binding fragment thereof can efficiently and specifically recognize CD45, can effectively detect CD45, and can be used for immunohistochemistry exemplarily.

The invention belongs to the technical field of medical diagnosis, and discloses a quantum multicolor immune digital pathological diagnosis analysis system, which comprises the following steps: acquiring high-resolution digital images of an immunohistochemical or immunofluorescence slice and a slide, and analyzing multicolor signal distribution in the images to obtain a quantum chromatographic image set; pixel-level color separation and intensity quantization are carried out on the quantum chromatographic image set, and a quantum intensity index set of each pixel is generated; performing multi-target color overlay analysis and post-translational modification protein specificity evaluation on the quantum intensity index set to construct a multi-color modification index set; identifying a single cell boundary and a multi-cell community based on the multicolor modification index set, and extracting a cell morphological parameter and a spatial adjacency relation to obtain a cell quantum analysis set; performing consistency correction and traceable recording by applying an automatic quality control mechanism, and generating a digital diagnosis report; the accuracy of accurate qualitative and quantitative analysis of immunohistochemistry and immunofluorescence is greatly improved.

The invention relates to the technical field of antibodies, and provides an anti-CD45 antibody and application thereof, the antibody comprises at least one of the following CDRs: a heavy chain variable region CDR: an amino acid sequence of SEQ ID NO: 1-3 or a conservatively modified form thereof; and a light chain variable region CDR: SEQ ID NO: 4-6 or an amino acid sequence in a conservative modification form thereof. The antibody or the antigen binding fragment thereof can efficiently and specifically recognize CD45, can effectively detect CD45, and can be used for immunohistochemistry exemplarily.

The invention discloses DLL3 serving as a cervical neuroendocrine cancer treatment target and application of the DLL3, and belongs to the technical field of biology. The invention discloses specific expression of a DLL3 gene in cervical neuroendocrine carcinoma (NECC) and application of the DLL3 gene as a therapeutic target. Single cell sequencing and immunohistochemistry find that a DLL3-NOTCH1 / 2 signal axis is activated in NECC, and functional experiments prove that the DLL3-NOTCH1 / 2 signal axis drives malignant progression by promoting tumor proliferation and inducing T cell depletion. In addition, the invention also constructs an NECC organ-TILs co-culture model, and verifies the synergistic effect of the DLL3 targeted drug AMG757 combined with EP chemotherapy. The invention provides new target selection and theoretical basis for precise diagnosis and treatment of NECC, and has important clinical transformation value.

The invention relates to the field of image processing, in particular to a multi-immunohistochemical image processing and analyzing method and system. The method comprises the following steps: acquiring multiple immunohistochemical images at a plurality of time points, and performing sequential serialization fitting to obtain an immunohistochemical image sequence; performing depth visual semantic recognition and frame-by-frame segmentation reconstruction on the immunohistochemical image sequence, and constructing an image frame sequence of each marker; performing cell spatial distance change calculation and spatial expression correlation mining according to the image frame sequence of each marker to generate a time sequence behavior feature of each marker; and carrying out frame-by-frame organization structure analysis on the image frame sequence of each marker to obtain a three-dimensional organization structure model of each region. According to the method, accurate and efficient tissue structure evaluation is realized, and a personalized quantitative diagnosis result is provided.

The invention discloses pyruvate carboxylase (PC) serving as a biomarker for detecting endometriosis and application of the pyruvate carboxylase (PC) to treatment of the endometriosis. The biomarker can be used for detecting the expression level of PC in an endometrial tissue sample through an immunohistochemical method, and when the IHC score is greater than or equal to 4, a subject is judged to be at a high risk of endometriosis or suffered from the endometriosis. Meanwhile, the invention provides an application of drugs (including specific siRNA, ZY-444, octyl gallate and the like) for inhibiting PC expression in treatment of endometriosis, and a corresponding treatment method. The invention provides a new biomarker, target spot and scheme for detection and treatment of endometriosis, and has important clinical application value.

The invention discloses a mammary gland immunohistochemical Ki-67 image segmentation method based on an attention mechanism, and the method comprises the following steps: obtaining a mammary gland immunohistochemical Ki-67 image, and carrying out the segmentation processing of the mammary gland immunohistochemical Ki-67 image, and obtaining mammary gland immunohistochemical Ki-67 image blocks; taking the breast immunohistochemical Ki-67 image block as input, taking the corresponding cell type classification result as output, and training a pre-constructed breast cell segmentation model; a mammary gland cell segmentation model is constructed based on a VGG16 network and a cooperative attention mechanism of a space and a channel; segmenting a mammary gland immunohistochemical Ki-67 image to be predicted into a plurality of image blocks, and inputting the image blocks into the trained mammary gland cell segmentation model for segmentation; and obtaining a distribution density map of classification results of different types of cells. The invention relates to the technical field of image segmentation, and by coordinating the relationship between spatial features and channel features and enhancing the guiding capability of the features, semantic feature differences are effectively relieved, and the precision, flexibility and adaptability of tumor cell segmentation are remarkably improved.

An oncological foundation model is trained with broad, multimodal data to make predictions concerning a variety of different types of cancers. For example, the foundation model may make use of medical images drawn from radiology and pathology, as well as immunohistochemistry data; the presence or absence of biomarkers for particular diagnoses; patient history data; patient demographic data; and other forms of medical data. When using medical images, whole medical images as well as feature sets derived from the medical images may be used. The foundation model may have both causal predictive abilities as well as generative abilities.

The invention relates to the technical field of biomedical image processing, and discloses a multi-fluorescence immunohistochemical image intelligent analysis method based on deep learning. The method comprises the following steps: acquiring image data through image acquisition equipment, and performing data integrity verification, format conversion and the like to obtain a standard image data set; performing noise removal and brightness equalization preprocessing on the image based on a preset rule, and extracting image features by using a deep learning model; and finally carrying out region segmentation and object identification according to the features. According to the method, full-process automation of multiple fluorescence immunohistochemical images from collection to analysis is realized, and the accuracy, efficiency and reliability of image analysis are effectively improved through standardized processing, adaptive preprocessing and deep learning feature extraction and analysis of image data; powerful technical support is provided for biomedical research and clinical diagnosis, and the method has important application value.

The present invention relates to the field of biotechnology. Specifically, the present invention provides a monoclonal antibody, preparation method, and application of tyrosine iodinated EGFR protein. The present invention prepares tyrosine iodinated EGFR protein antigen peptides, immunizes mice to prepare monoclonal antibodies, and utilizes phage display technology to select and express relevant antibodies using expression vectors. ELISA screening and immunohistochemistry and cell fluorescence detection yield two highly sensitive and specific monoclonal antibodies, M018 and M025. The monoclonal antibodies obtained by screening can be used for the detection and monitoring of tyrosine iodinated modification at position 845 of the EGFR protein, providing support for tumor diagnosis and the development of anti-tumor drugs.

A reagent kit, staining method, and application for combining dual immunohistochemistry with elastin fiber staining. The reagent kit includes a combination of primary antibodies, consisting of anti-CK7 and anti-CD34 monoclonal antibodies from different species, such as rabbit anti-human CK7 monoclonal antibody and mouse anti-human CD34 monoclonal antibody. By selecting CK7 and CD34 as the primary antibody combination, the growth pattern of tumor epithelium can be accurately indicated, and the proliferation and thickening of alveolar septal fibrous tissue caused by tumors can be clearly revealed, as opposed to structural changes of alveoli induced by other factors. Combined with independent Victoria blue staining, the elastin fibers of the walls of arteries and veins, as well as the pleura of the lungs, can be clearly visualized, aiding in the assessment of the integrity of elastin fibers on the lung surface and in determining the extent of tumor infiltration.

Methods and systems for analysing the cellular composition of a sample are described, comprising: providing an image of the sample in which a plurality of cellular populations are associated with respective signals and classifying a plurality of query cells in the image between a plurality of classes corresponding to respective cellular populations in the plurality of cellular populations. This is performed by providing a query single cell image to an encoder module of a machine learning model to produce a feature vector for the query image, and assigning the query cell to one of the plurality of classes based on the feature vector for the query image and feature vectors produced by the encoder module for each of a plurality of reference single cell images. The machine leaning model comprises: the encoder module, configured to take as input a single cell image and to produce as output a feature vector the single cell image, and a similarity module configured to take as input a pair of feature vectors for a pair of single cell images and to produce as output a score indicative of the similarity between the single cell images. Thus, the machine learning model can be obtained without the need for an extensively annotated dataset. The methods find use in the analysis of multiplex immunohistochemistry / immunofluorescence in a variety of clinical contexts.

The invention relates to the technical field of biomedicine. The invention provides a phosphorylated protein marker for angiogenesis of glioma and application of the phosphorylated protein marker. Through a series of analysis such as iTRAQ quantitative phosphorylated proteomics, KEGG signal channel enrichment, a kinase spectrum, glioblastoma transcriptome high-throughput sequencing data and immunohistochemistry, it is determined that significantly different phosphorylated proteins and related signal channels can significantly affect neuroglioma angiogenesis; and the phosphorylated protein changes along with tumor progression, and is a phosphorylated protein marker and a potential therapeutic target for glioma angiogenesis.

The invention relates to the technical field of optics, and discloses a visualization method of a biological tissue three-dimensional full-information atlas, which comprises the following steps of: acquiring image data, electron microscope data, mechanical data, protein distribution, omics information and histological staining images of biological tissues by using various biological visualization technologies, and correspondingly processing the acquired data to obtain a three-dimensional full-information atlas of the biological tissues; finally, organization information fusion and digital display are achieved. According to the method, a cross-scale feature correlation algorithm framework is innovatively established, and multi-source heterogeneous data fusion is performed on medical image topological data (CT / MRI), ultrastructure scanning data (SEM / TEM), molecular positioning information (immunofluorescence, immunohistochemistry and enzyme immunoassay), omics maps (space transcriptome / proteome) and high-resolution tissue staining data. The data island dilemma caused by traditional single-mode analysis is broken through, and full-scale visualization from nanoscale molecular distribution to centimeter-level organ tissue structure-function relationship is realized for the first time.

The invention relates to the field of automation of pathological slide staining, in particular to an automation device for cytological slide staining and histological immunohistochemistry and special staining based on an advanced fluid control technology, which comprises an upper centrifugal component and a lower slide staining component, and the slide-making and dyeing assembly comprises a circular or arc-shaped dyeing turntable and a matched traditional dyeing or immunohistochemical and special dyeing liquid path component. According to the invention, a traditional transfer mode is not adopted, such as a pipette arm, a pipette and other structures which are easy to generate mechanical faults, key function modules such as sample oscillation, centrifugation, flaking, dyeing and the like are integrated in one machine, cytology sample pretreatment and flaking dyeing operations are fully automatically completed, and special dyeing functions such as histology immunohistochemistry and the like can be compatible; tedious steps are greatly simplified, the functional diversity, efficiency and stability of the equipment are improved, and the maintenance cost of the equipment is also reduced.

The invention discloses a monoclonal antibody BY013 combined with African swine fever virus P30 protein and application of the monoclonal antibody BY013. The invention provides an IgG antibody which is composed of a light chain and a heavy chain. CDR1, CDR2 and CDR3 in the heavy chain variable region are sequentially shown as the 47 to 54 , the 72 to 79 and the 118 to 130 in SEQ ID NO: 1; cDR1, CDR2 and CDR3 in a light chain variable region are sequentially as shown in the 49 to 60 , the 78 to 80 and the 117 to 124 in SEQ ID NO: 3. The invention also protects the application of any one of the IgG antibodies in preparation of products. The product has the functions that the product is used for being combined with an African swine fever virus P30 protein fragment; the antibody is used for binding African swine fever virus P30 protein; the antibody is used for binding African swine fever virus. The IgG antibody provided by the invention can be used for multiple purposes of western blot, immunohistochemistry, flow cytometry, ELISA (Enzyme-Linked Immunosorbent Assay) and the like, and can be used as an important tool for ASFV detection and structural analysis of P30 protein of ASFV detection.

The present invention provides an immunohistochemical staining machine, comprising a machine body, and a slide rack, a liquid immersion mechanism, a Y-axis moving component, a liquid removal chamber, a reagent adding mechanism, an incubation mechanism, a bidirectional clamping mechanism and a first rotating table installed in the machine body. Through the periodic rotation of the first rotating table, after the first rotating table drives the bidirectional clamping mechanism to rotate, two clamping members can be aligned with the slide rack and the reagent adding mechanism at the same time, or respectively aligned with the liquid removal chamber and the incubation mechanism at the same time, and the two clamping members can both realize the operation of clamping and placing the slide, and the bidirectional clamping mechanism can drive the two clamping members to move closer to or away from each other, so that each clamping member can send the clamped slide into the corresponding mechanism, and the experimental operation steps do not interfere with each other. In this way, the transportation stroke and number of slides are reduced, which is more efficient than the efficiency of repeated transportation of a single slide in conventional immunohistochemical staining equipment, and greatly simplifies the operation process of immunohistochemistry.

The present invention relates to the field of medical testing. Specifically, the present invention provides a diagnostic model for predicting the prognosis of CAR-T cell immunotherapy for gastric cancer and its application. For the first time, the present invention systematically analyzed the content and spatial distribution map of the microenvironment components of CLDN18.2-positive gastric cancer tissue samples by integrating multiple fluorescent immunohistochemistry detection and whole-slice digital imaging quantitative analysis methods. Through multidimensional evaluation of the tumor microenvironment under the treatment background of CT041, a diagnostic model for predicting the prognosis of CAR-T cell immunotherapy for gastric cancer was established for the first time, which enables accurate screening of beneficiary populations and risk stratification before treatment, guides treatment selection, and improves treatment efficacy.

This invention discloses a breast cancer classification method based on Piezo1 expression. After obtaining tumor tissue samples from patients, the method detects the Piezo1 protein expression level using immunohistochemistry and classifies them into high-expression and low-expression types according to a validated scoring standard. This classification result guides individualized treatment, with high-expression patients recommended for treatment regimens including inhibitors of mechanotransmission pathways. By integrating tumor mechanotransmission characteristics into the clinical classification system, this invention can identify a subgroup of breast cancer driven by an abnormal mechanotransmission microenvironment that cannot be distinguished by traditional molecular classification. This not only improves and supplements the existing classification framework, making the understanding of breast cancer heterogeneity more comprehensive, but also more accurately predicts the invasiveness, metastasis potential, and poor prognostic risk of these patients.

Microglial spatial heterogeneity remains a crucial yet poorly studied question in light of potential cell-directed therapies for Alzheimer`s disease (AD). Little is known about the dynamics of spatially distinct microglia states, which are either adjacent or non-associated with the plaque site, and their selective contributions to neurodegeneration in vivo. So far, research has essentially focused on pathology-associated microglia. Here, we combined novel multicolor fluorescence fate mapping, single-cell transcriptional analysis, epigenetic profiling, advanced immunohistochemistry and computational modelling to comprehensively characterize the relation of plaque-associated and non-plaque- associated microglia during neurodegeneration. This approach enabled us to identify and characterize non-plaque-associated microglia as a unique and highly dynamic microglial state in a mouse model of AD. Non-plaque-associated microglia modulate network expansion, quickly adapt to environmental cues and their transition to plaque-associated microglia can be specifically modulated during disease, contrary to their reputation as a passive bystander subpopulation. This description of the dynamics of spatially segregated microglial states and their distinct molecular features may therefore open promising new avenues for state-specific therapeutic interventions during neurodegeneration.

The present invention provides a biomarker combination for diagnosing Hirschsprung's disease, which is any one of combination 1, combination 2, and combination 3; wherein, the combination 1 is a combination of SCGN, PGP9.5, and S100; the combination 2 is a combination of SCGN and PGP9.5; the combination 3 is a combination of SCGN and S100. The present invention also provides the application of the above biomarker combination in the preparation of a diagnostic reagent for Hirschsprung's disease. At the same time, an immunohistochemistry kit is provided. The present invention discovers that SCGN can effectively identify ganglion cells in rectal mucosal biopsy specimens / entire colon specimens of children with Hirschsprung's disease, and the diagnostic sensitivity and specificity are higher than the existing detection schemes after combining with PGP9.5 and / or S100; the present invention provides a new, accurate, and sensitive detection method for the diagnosis of Hirschsprung's disease.

1. Name of the product in this design: Fully Automatic Immunohistochemistry Independent Temperature Controlled Individual Drop Staining Machine (CNT310). 2. Purpose of this design: For staining samples before pathological analysis. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The present application relates to the technical field of incubation bin assembly, and aims to provide an incubation bin liquid discharge device and an immunohistochemical device to solve the technical problem of low liquid discharge efficiency of the incubation bin in the prior art, which affects incubation and reaction operation. The immunohistochemical device comprises a bottom plate and an incubation bin assembled on the bottom plate, and further comprises an incubation bin liquid discharge device assembled on the bottom plate, wherein the incubation bin liquid discharge device is connected with the incubation bin in correspondence, and the incubation bin liquid discharge device comprises a transfer bin and a liquid discharge channel connected at one end of the transfer bin, the other end of the liquid discharge channel is provided with a liquid inlet, and the liquid inlet is used for butting against a waste liquid pipe at the bottom of the incubation bin; a quick liquid discharge device is connected on the liquid discharge channel or the transfer bin, and the quick liquid discharge device is used for sucking the transfer bin to quickly suck the waste liquid in the waste liquid bin into the transfer bin.

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-terminal deoxynucleotidyl transferase (TdT) antibody and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the antibody are respectively shown as SEQ ID NO.8-10. The antibody disclosed by the invention can specifically recognize TdT protein naturally expressed in cells and tissues, has the advantages of high specificity, high affinity, high sensitivity and the like when being used for immunoblotting, immunohistochemistry and other immunodetection systems, is beneficial to reducing false positive and false negative rates in pathological diagnosis, improves the accuracy of immunodiagnosis, and has a good application prospect. The method has wide application potential in the field of immunological detection of living biological samples. In addition, the antibody disclosed by the invention has cross-species reaction characteristics on homologous TdT proteins of human, mice and rats, so that the application scene of the antibody is greatly expanded.